Fig. 3From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceSubgroup analysis – association of IRD and RD with PFSBack to article page